Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Nov 1;4(11):e2131836.
doi: 10.1001/jamanetworkopen.2021.31836.

Screening in High Schools to Identify, Evaluate, and Lower Depression Among Adolescents: A Randomized Clinical Trial

Deepa L Sekhar  1 , Eric W Schaefer  2 , James G Waxmonsky  3 , Leslie R Walker-Harding  4 , Krista L Pattison  1 , Alissa Molinari  1 , Perri Rosen  5 , Jennifer L Kraschnewski  1   2   6
Affiliations
Randomized Controlled Trial

Screening in High Schools to Identify, Evaluate, and Lower Depression Among Adolescents: A Randomized Clinical Trial

Deepa L Sekhar et al. JAMA Netw Open. .

Abstract

Importance: Adolescent major depressive disorder (MDD) prevalence has nearly doubled in the past decade. The US Preventive Services Task Force endorses universal adolescent MDD screening in primary care; however, most adolescents lack preventive health care, resulting in worsening disparities in MDD screening and treatment.

Objective: To evaluate the effectiveness of universal adolescent MDD screening in the school setting in an effort to reduce disparities and improve MDD identification and treatment initiation.

Design, setting, and participants: This randomized clinical trial, conducted from November 6, 2018, to November 20, 2020, compared the usual school practice of targeted or selected screening based on observable behaviors of concern with universal MDD screening. Students within an identified school were randomized by grade to 1 of the 2 study groups. Study groups were compared using mixed-effects logistic regression. Participants included students in grades 9 through 12 enrolled at 1 of the 14 participating Pennsylvania public high schools.

Interventions: In targeted screening, students with behaviors prompting concern for MDD were referred to the Student Assistance Program (SAP), mandated in all Pennsylvania schools. The SAP determined follow-up recommendations. In universal screening, all students completed the Patient Health Questionnaire-9 (PHQ-9); students with positive scores proceeded to SAP. The universal screening group could also have targeted referral to SAP for concerning behavior independent of the PHQ-9.

Main outcomes and measures: The primary outcome was initiation of MDD treatment or services based on data collected by school SAP teams during the academic year.

Results: A total of 12 909 students were included (median age, 16 years [range, 13-21 years]; 6963 male [53.9%]), of whom 2687 (20.8%) were Hispanic, 2891 (22.4%) were non-Hispanic Black, 5842 (45.3%) were non-Hispanic White, and 1489 (11.5%) were multiracial or of other race or ethnicity. A total of 6473 students (50.1%) were randomized to universal screening, and 6436 (49.9%) were randomized to targeted screening. Adolescents in the universal screening group had 5.92 times higher odds (95% CI, 5.07-6.93) of being identified with MDD symptoms, 3.30 times higher odds (95% CI, 2.49-4.38) of SAP confirming follow-up needs, and 2.07 times higher odds (95% CI, 1.39-3.10) of initiating MDD treatment. No differences were identified in initiation for planned subgroup analyses by sex or race and ethnicity.

Conclusions and relevance: In this randomized clinical trial, universal school-based MDD screening successfully increased identification of MDD symptoms and treatment initiation among adolescents, confirming the value of this approach to address this rising public health concern.

Trial registration: ClinicalTrials.gov identifier: NCT03716869.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: In the past 3 years, Dr Sekhar reported receiving funding from Pfizer through the American Academy of Pediatrics, the Penn State Clinical and Translational Science Awards Program, and a Eugene Washington Patient-Centered Outcomes Research Institute Engagement Award. In the past 3 years, Dr Waxmonsky reported receiving research funding from Supernus and consulting with Intracellular Therapeutics and Adlon Pharmaceuticals. Dr Kraschnewski reported receiving grants from Patient-Centered Outcomes Research Institute and the Agency for Healthcare Research and Quality during the conduct of the study and grants from Merck outside the submitted work, and she reported currently serving on an advisory board for Sanofi to address health disparities for influenza vaccination in primary care. No other disclosures were reported.

Figures

Figure.
Figure.. Study Flow Diagram
See this image and copyright information in PMC

Comment in

References

    1. Healthy People.gov. Mental health and mental disorders. Accessed February 24, 2021. https://www.healthypeople.gov/2020/data-search/Search-the-Data?nid=4813
    1. Siu AL; US Preventive Services Task Force . Screening for depression in children and adolescents: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(5):360-366. doi:10.7326/M15-2957 - DOI - PubMed
    1. Zenlea IS, Milliren CE, Mednick L, Rhodes ET. Depression screening in adolescents in the United States: a national study of ambulatory office-based practice. Acad Pediatr. 2014;14(2):186-191. doi:10.1016/j.acap.2013.11.006 - DOI - PMC - PubMed
    1. Sekhar DL, Ba DM, Liu G, Kraschnewski JL. Major depressive disorder screening remains low even among privately insured adolescents. J Pediatr. 2019;204:203-207. doi:10.1016/j.jpeds.2018.07.086 - DOI - PubMed
    1. Irwin CE Jr, Adams SH, Park MJ, Newacheck PW. Preventive care for adolescents: few get visits and fewer get services. Pediatrics. 2009;123(4):e565-e572. doi:10.1542/peds.2008-2601 - DOI - PubMed

Publication types

Associated data